BioCentury | Oct 26, 2020
Emerging Company Profile

Serial dealmaker Glick to lead cancer start-up Scorpion with familiar VCs supplying $108M

...Due Inc., a separate subsidiary that houses cGAS...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Blocking cGAS for colitis

...DISEASE CATEGORY: Gastrointestinal INDICATION: Colitis Colitis may be treatable by targeting cGAS, a cytosolic DNA sensor...
...the cGAS product cGAMP in colon tissue. In wild-type mice exposed to the chemical, a cGAS...
...weight loss, clinical disease scores and histological signs of inflammation and intestinal architecture damage. The cGAS...
BioCentury | Jun 23, 2020
Distillery Therapeutics

Blocking cGAS signaling for alcohol-related liver disease

...DISEASE CATEGORY: Hepatic INDICATION: Liver disease Targeting the cGAS-IRF3 signaling pathway by inhibiting cGAS or the...
...GJB1 could treat alcohol-related liver disease. In liver samples from alcoholic-related liver disease patients, high cGAS...
...more severe disease. In mice with liver disease due to alcohol consumption, systemic or hepatocyte-specific cGAS...
BioCentury | Jun 2, 2020
Deals

Personalized kidney play Chinook rounds out pipeline, lands on NASDAQ via Aduro deal

...The biotech has a STING agonist that is partnered with Novartis AG (NYSE:NVS; SIX:NOVN), a cGAS-STING...
...million. Targets APRIL (TNFSF13) - Tumor necrosis factor (TNF) ligand superfamily member 13 cGAS - cGAMP synthase...
BioCentury | Apr 25, 2020
Deals

Novartis business development stays on course during COVID-19

...entered a collaboration and acquisition option deal for the IFM Due subsidiary, which is developing cGAS...
...do deal-making.” Sheail expects more deals to close in the coming months. Targets cGAS - cGAMP synthase...
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...GF Securities, and Arch Venture Partners Executive Chair: Sandra Peterson Patents: Undisclosed Targets cGas - cGAMP synthase...
BioCentury | Dec 2, 2019
Financial News

IFM Therapeutics gets $55.5M to launch incubator and new subsidiaries

...up to $840 million in upfront and milestone payments. IFM Due is developing antagonists of cGAS...
...post of executive chairman. Seidel will also sit on the company’s board. Targets: cGAS - cGAMP synthase...
BioCentury | Oct 1, 2019
Finance

STING start-up STipe first to emerge from Novo incubator

...intends to develop first-in-class drugs that target protein-protein interactions of the STING signaling pathway. The cGAS-STING...
...fragments of abnormal DNA, such as microbial or damaged human DNA, and triggers inflammatory signaling. cGAS...
...board will include Tobin, Døssing, Wellington’s Regina Hodits and Sunstone’s Sten Verland. Targets: cGAS - cGAMP synthase...
BioCentury | Sep 5, 2019
Company News

In third pharma deal, IFM partners cGAS-STING unit with Novartis

...undisclosed but comparable to a "very healthy VC round." IFM Due is developing antagonists of cGAS...
...than agonize, the STING pathway (see "IFM Launches Subsidiary for cGAS, STING Inhibitors" ). The cGAS-STING...
...a new unit early next quarter to develop its non-NLRP3 inflammasome programs. Targets: cGAS - cGAMP synthase...
BioCentury | Jun 4, 2019
Distillery Techniques

Tool compounds for probing the role of human cGAS in inflammatory diseases

...compound Small molecule inhibitors of human cGAS could be used to probe the role of cGAS-dependent...
...line and in primary human macrophages, the cGAS inhibitors inhibited interferon β (IFNB1) expression downstream cGAS...
...in animal models of inflammatory diseases. DESCRIPTION: Human cGAMP synthase (cGAS) inhibitors for probing the role of cGAS-dependent...
Items per page:
1 - 10 of 31